The visible transformation of a common bruise is an ancient colorimetric reaction that is dependent upon the enzyme
HO.
HO is the first and rate-limiting step in the degradation of heme (purple hue) to biliverdin (green hue), and finally to bilirubin (yellow hue) (
Fig. 20.2). Three known isoforms of
HO exist: HO-1, -2, and -3. In the context of cellular adaptation to stress, HO-1 appears to be the most relevant isoform. HO-1 is identical to HSP32 and is highly inducible by a variety of cellular stressors and stimuli, including heme,
NO, cytokines, heavy metals, hyperoxia, hypoxia, endotoxin, heavy metals, and heat shock (
16).
In vitro studies involving gene transfection or gene transfer approaches have provided clear evidence that HO-1 confers

cytoprotection (
16,
18). For example, overexpression of HO-1 conferred protection against oxygen toxicity, hemoglobin toxicity, tumor necrosis factor (
TNF)-
α-mediated apoptosis, and
Pseudomonas-mediated cellular injury and apoptosis. Experiments in animal models, involving either pharmacologic induction of HO-1 or genetic overexpression of HO-1, confirm that HO-1 confers cytoprotection in vivo. Induction of HO-1, by intravenous hemoglobin administration, protected rats against the lethal effects of endotoxemia. Lung epithelial overexpression of HO-1, via an adenovirus vector, conferred protection in rats exposed to hyperoxia; cardiac-specific overexpression conferred protection in a murine model of ischemia. There is also interest in HO-1-mediated cytoprotection in the field of transplant biology. In a cardiac xenograft transplantation model, increased expression of HO-1 improved graft survival.
The by-products of
HO enzymatic activity include carbon monoxide (
CO), bilirubin, and ferritin (
Fig. 20.2), and each of these by-products has been postulated to play a role in cytoprotection. Ferritin is known to protect against oxidant stress, and bilirubin can function as a potent antioxidant. The most recent work in the field implicates CO-related cell signaling as the key component of HO-1-mediated cytoprotection (
19,
20,
21). For example, HO-1-derived
CO appears to play an important role in the host defense to severe infection in a murine model of polymicrobial sepsis (
22).
CO shares a variety of properties with
NO, including neurotransmission, regulation of vascular tone, and activation of soluble guanylate cyclase. The reported biologic effects of
CO include potent anti-inflammatory effects (via the mitogen-activated protein kinase [
MAPK] pathway), anti-apoptotic effects, and antioxidant effects. In vivo administration of low concentrations of inhaled
CO protected rats against hyperoxia-mediated acute lung injury, and administration of exogenous
CO to cardiac tissue protected the tissue against ischemia-reperfusion injury following transplantation. Several experimental studies have confirmed these initial results, demonstrating that
CO inhalation or pharmacologic administration of CO-releasing drugs is cytoprotective in several different animal models of sepsis and acute lung injury (
23,
24). These studies are particularly intriguing because the amount of
CO administered in these experiments is within the range administered to patients undergoing lung diffusion scans. Unfortunately, a recent study in nonhuman primates showed that the doses of inhalational
CO that produced anti-inflammatory effects also resulted in relatively high and potentially toxic levels of carboxyhemoglobin (CO-Hb) levels (>30%) (
25). However, the anti-inflammatory effects of
CO were recently examined in a randomized, doubleblind, placebo-controlled, two-way crossover trial in which healthy volunteers were injected with a 2 ng/kg dose of lipopolysaccharide (
LPS). Inhalation of 500 ppm
CO versus air had no effect on the inflammatory cytokine production, though no adverse side effects were observed (CO-Hb levels increased to as high as 7%) (
26). Conversely, inhalation of
CO by patients with stable Chronic Obstructive Pulmonary Disease (
COPD) at doses of 100-125 ppm for 2 hours/day for 4 days was effective in improving lung inflammation and function (
27). Clearly, further studies are required. In addition, as yet there have been no clinical trials of CO-releasing agents in humans.